Medication info

Prilencapsule 25mg (Pregabalin)

Prescription medicationHard capsuleOralApproval withdrawn
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
You & Life Sciences Co., Ltd.
Appearance
A hard capsule with pale yellow upper part and white lower part containing white powder
Packaging
30 capsules/bottle
Approval status
Approval withdrawn

MFDS item code 202001439 · Approved 2020.02.29

This product's status changed to Approval withdrawn on 2025.02.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of epilepsy (partial seizures), and treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Because this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150, maximum dose 600, BID or TID ≥30-<60: Starting dose 75, maximum dose 300, BID or TID ≥15-<30: Starting dose 25-50, maximum dose 150, QD or BID <15: Starting dose 25, maximum dose 75, QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as indicated under the administration regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
You & Life Sciences Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of epilepsy (partial seizures), and treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This drug is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in adults, whether or not accompanied by secondary general symptoms. Additionally, it is effective in alleviating symptoms of fibromyalgia, thus aiding in the treatment of various neurological disorders.

How to take

Adult dose

This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Because this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150, maximum dose 600, BID or TID ≥30-<60: Starting dose 75, maximum dose 300, BID or TID ≥15-<30: Starting dose 25-50, maximum dose 150, QD or BID <15: Starting dose 25, maximum dose 75, QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as indicated under the administration regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This drug may increase the risk of suicidal thoughts or behaviors, so changes in mood or symptoms of depression should be closely monitored during treatment. Patients with allergies to the components of this drug or those with specific genetic lactose degradation disorders should not take this drug. Diabetic patients may need to adjust the dosage of their blood glucose control medications due to potential weight gain after taking this drug. This drug can cause severe allergic reactions such as angioedema, so if swelling in the face or neck or difficulty breathing occurs, it should be discontinued immediately. Elderly patients may have an increased risk of falls due to dizziness or drowsiness when taking this drug, particularly during the initial dose. Temporary blurred vision or changes in vision may occur, and if symptoms persist, a consultation with a physician is advised. Withdrawal symptoms such as insomnia, headaches, and anxiety may occur upon discontinuation of this drug, so the dosage should be gradually reduced according to the physician's instructions. This drug has a risk of abuse, so patients with a history of substance abuse should take it with greater caution and notify their physician if any unusual behavior occurs. Patients with impaired kidney function may require dosage adjustment. Patients with heart disease or congestive heart failure should exercise caution while taking this drug. The risk of central nervous system depression may increase when used in combination with opioid analgesics, so a physician should be consulted. This drug may cause dizziness and drowsiness, so driving or operating hazardous machinery should be avoided after taking it. During early pregnancy, it may affect the fetus, so pregnant women are advised not to take it, and women of childbearing age should use effective contraception. Lactating women should consult with their physician regarding discontinuing breastfeeding or the drug, as this drug may be transmitted through breast milk. In the case of an overdose, symptoms such as confusion, drowsiness, and seizures may appear, necessitating an immediate visit to a medical institution. It should be kept out of reach of children and not transferred to other containers for safety. This drug has minimal drug interactions, but caution should be exercised when taken with other central nervous system depressants.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 176 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • thoughts of suicide
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • insomnia
  • confusion
  • disorientation
  • irritability
  • feelings of relief
  • decreased libido
  • depersonalization
  • sexual hyperesthesia
  • restlessness
  • anxiety
  • mood fluctuations
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • memory loss
  • attention deficit
  • memory dysfunction
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory reduction
  • calmness
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • tonic-clonic seizures
  • decreased reflexes
  • movement disorders
  • psychomotor agitation
  • positionally-induced dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • taste loss
  • writing disability
  • diplopia
  • vertigo
  • hypogonadism
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • hypersalivation
  • gastroesophageal reflux disease
  • oral sensory decline
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle twitching
  • throat pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • fatigue
  • delirium
  • paralysis
  • affective disorders
  • agitation
  • restlessness
  • exacerbation of seizures
  • coma
  • death
  • respiratory failure

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is important to maintain a storage temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with pale yellow upper part and white lower part containing white powder

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.